Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284874 | 0.99 | CDC7 (0.46) | CDC7CNR2KCNH2KDM4ECYP19A1 | |
| SCHEMBL4291497 | 0.82 | GRM2 (0.39) | CDC7KDM4ECYP19A1SLC9A1GRM2 | |
| SCHEMBL4297826 | 0.81 | CDC7 (0.44) | CDC7CNR2KDM4ECYP19A1 | |
| SCHEMBL3667322 | 0.79 | ROCK2 (0.43) | CDC7CNR2KDM4ECYP19A1SLC9A1 | |
| SCHEMBL4292592 | 0.77 | GRM2 (0.41) | CDC7KDM4ECYP19A1SLC9A1GRM2 | |
| SCHEMBL4293011 | 0.76 | KDM4E (0.42) | KDM4E | |
| SCHEMBL3669940 | 0.75 | CYP19A1 (0.48) | CDC7CYP19A1SLC9A1GRM2 | |
| SCHEMBL4292554 | 0.71 | CDC7 (0.44) | CDC7CYP19A1SLC9A1GRM2 | |
| SCHEMBL4295553 | 0.70 | CDC7 (0.46) | CDC7CYP19A1SLC9A1GRM2 | |
| SCHEMBL4291234 | 0.70 | SMN1; SMN2 (0.51) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CDC7 8/4885CNR2 4160/4885KCNH2 1622/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CDC7 8/4885CNR2 4160/4885KCNH2 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.